The US Food and Drug Administration said on Wednesday that currently available COVID-19 vaccines are not well matched against the BA.2 sub-variant of Omicron, although booster doses help protect against severe outcomes.
The comments were made at a meeting of the FDA's outside experts to discuss the timing of additional COVID-19 vaccine boosters and people eligible for extra shots.